Ranbaxy Laboratories Limited (RLL), announced today that the Company has received final approval in Canada to manufacture and market Ran-Simvastatin 5 mg, 10 mg, 20 mg, 40 mg and 80 mg tablets (Simvastatin) from Health Canada, Therapeutic Products Directorate (TPD).  Total generic market size of Simvastatin tablets in Canada is $153 million ($CAD) [IMS-CDH: October 2008].  Ran-Simvastatin tablets are indicated for use as a lipid metabolism regulator.

“We look forward to marketing this organically developed product in all strengths that will be commercialized at an affordable price that will be beneficial to both the Canadian healthcare system, and most importantly, to Canadian patients.  Ran-Simvastatin represents the second approval granted to RPCI in July that will further expand the depth and breadth of our product portfolio of molecules that have clinical utility and value.  We plan to launch Ran-Simvastatin in a September timeframe,” said Paul Drake, President, RPCI.

Also Read   Related Stories News Now - Sanghvi Movers net profit at Rs 23.10 crore - Mahindra Lifespace's Q1 PAT register a 7% growth - Jones Lang LaSalle Meghraj Launches Office In Ahmedabad - Projects investment down in Q1 of current fiscal: ProjectsToday Study - Barclays Bank PLC opens branch in Ahmednagar - Kinley Unveils An All New 'Vishwas Karo' Communication Initiative For The Consumers

Also Read   Related Stories News Now - Markets languish as heavyweights drag - NEWSALERT: Doon Express derails near Jaunpur, UP - Cardamom recovers 0.16% on spot demand - Lead down on subdued demand, weak overseas cues - Mentha oil rebounds as demand picks up More

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development.  The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.

New Ipad Application :Business Standard's all new IPad App Click here to download for free Other Stories      - Markets languish as heavyweights drag - NEWSALERT: Doon Express derails near Jaunpur, UP - Cardamom recovers 0.16% on spot demand - Lead down on subdued demand, weak overseas cues - Mentha oil rebounds as demand picks up

Read Business news in  Advertisements -  India's no. 1 Property Site. Click here to know more -  "Discover The Power of One" -  Help a Child Achieve her. Click to know more -  Watch The Film Here. Click here to know more.. -  Learn How One City is Running on FOOD SCRAPS. -  1 billion in saving for Unilever without any tangles. -  Helping doctors detect diseases earlier, saving costs & extending lives. -  Which is the best plan for your daughter -  Check out the TRUE COLOURS of your Stocks, Now for FREE! -  One of the leading business schools in the world.Know More -  2 Lac Apartments, 1 Lac House / Plots. Click here